Skip to Content

Generic Zioptan Availability

Zioptan is a brand name of tafluprost ophthalmic, approved by the FDA in the following formulation(s):

ZIOPTAN (tafluprost - solution/drops;ophthalmic)

  • Manufacturer: OAK PHARMS INC
    Approval date: February 10, 2012
    Strength(s): 0.0015% [RLD]

Has a generic version of Zioptan been approved?

No. There is currently no therapeutically equivalent version of Zioptan available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zioptan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Difluoroprostaglandin derivatives and their use
    Patent 5,886,035
    Issued: March 23, 1999
    Inventor(s): Shirasawa; Eiichi & Kageyama; Masaaki & Nakajima; Tadashi & Nakano; Takashi & Mori; Nobuaki & Sasakura; Hideshi & Matsumura; Yasushi & Morizawa; Yoshitomi
    Assignee(s): Asahi Glass Company Ltd. Santen Pharmaceutical Co., Ltd.

    A fluorine-containing prostaglandin derivative of the formula (1) (or a salt thereof) and a medicine containing it, particularly, a preventive or therapeutic medicine for an eye disease: ##STR1## wherein A is a vinylene group or the like, R.sup.1 is an aryloxyalkyl group or the like, R.sup.2 and R.sup.3 are hydrogen atoms or the like, and Z is OR.sup.4 (wherein OR.sup.4 is a hydrogen atom or an alkyl group) or the like.

    Patent expiration dates:

    • December 18, 2022
      ✓ 
      Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Method and composition for treating ocular hypertension and glaucoma
    Patent 9,999,593
    Issued: June 19, 2018
    Assignee(s): SANTEN PHARMACEUTICAL CO., LTD. ASAHI GLASS CO., LTD.

    The present invention relates to an ophthalmic aqueous composition containing PGF2α analogs for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2α analogs in an aqueous composition.

    Patent expiration dates:

    • May 28, 2029
      ✓ 
      Drug product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide